Fingerpaint Group Announces the Launch of Elevalt, an Optimized Omnichannel Solution
Fingerpaint Group announced the launch of Elevalt, an optimized omnichannel solution that was perfected over the past 6 years and features its 4Ps proprietary algorithms. Designed for use across all audiences and at every stage of the commercialization process, Elevalt serves as the foundation of the company’s data-driven approach to pharmaceutical marketing.
“Elevalt’s 4Ps proprietary algorithms––Profiling, Prediction, Progression, and Perception—work in tandem to evaluate and continuously optimize the performance of assets against precisely defined target audiences, automatically ensuring the next best personalized asset is being delivered,” said Rommel Fernandez, Chief Analytics Officer at Fingerpaint Group. “It is the closest you can come to replicating personal outreach in a digital world.”
Progressively built and fine-tuned over the past 6 years, Elevalt can quickly identify what’s working and how to best personalize messaging from the very first exposure, while leveraging an intricate customer profile.
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
